Uveitis is inflammation of the uveal tract (iris, ciliary body, and choroid) that...
- TapImmune begins patient enrolment for Phase ll trial of TPIV200
- Astellas reports positive Phase I data of gilteritinib combination
- Janssen reports positive Phase ll and lll data of imbruvica
- CEL-SCI reaches full enrolment in Phase lll trial of Multikine
- Nordic presents new Phase l/ll data of Betalutin
Realm doses first patient in Phase ll study of PR013
Realm Therapeutics has dosed the first patient in its Phase ll study of PR013 for the treatment of allergic conjunctivitis.
TapImmune begins patient enrolment for Phase ll trial of TPIV200
TapImmune has started enrolling patients in a Phase ll clinical trial of TPIV200 vaccine to treat women with triple-negative breast cancer (TNBC) and who have completed first-line surgery, radiotherapy/chemotherapy.
Sartorius Research Xchange Forum Promotes Interdisciplinary Exchange Between Science and Industry
Sartorius will be hosting its second Research Xchange Forum to promote interdisciplinary exchange between science and industry on the topics of regenerative medicine and cell therapy.
Astellas reports positive Phase I data of gilteritinib combination
Astellas Pharma has reported positive results from a Phase l study evaluating gilteritinib in combination with intensive chemotherapy in patients newly diagnosed with acute myeloid leukemia (AML).
Janssen reports positive Phase ll and lll data of imbruvica
Janssen-Cilag International has reported positive results from a pooled analysis that includes Phase ll and lll studies of imbruvica (ibrutinib) in patients with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
CEL-SCI reaches full enrolment in Phase lll trial of Multikine
CEL-SCI has reached the full enrolment stage in a Phase lll trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, injection) for the treatment of head and neck cancer.
Nordic presents new Phase l/ll data of Betalutin
Nordic Nanovector has unveiled updated results from its LYMRIT 37-01 Phase l/ll clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) to treat patients with relapsed/refractory (R/R) indolent NHL (iNHL) and third-line follicular lymphoma (3L FL).
Takeda reports positive Phase lll data of adcetris combination
Takeda Pharmaceutical Company and Seattle Genetics have reported positive results in a Phase lll clinical trial assessing adcetris (brentuximabvedotin) under a frontline combination chemotherapy regimen for untreated advanced classical Hodgkin's lymphoma.
Sophiris completes enrolment in Phase llb trial of topsalysin
Sophiris Bio has concluded enrolling patients in a Phase llb study that will evaluate the safety and tolerability of targeted intraprostatic administration of topsalysin to treat men with clinically significant localised prostate cancer.
Sartorius Lab Instrument’s Cubis® Balance Range Meets the Cleanability Requirements of the Pharmaceutical Industry
Balances in Satorius Lan Instrument's Cubis® product range have been designed for the demanding pharmaceutical environment, which is regulated by good manufacturing practices (GMP) and good laboratory practices (GLP).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.